Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising the steps of

• i) determining the activity of a 5-HT1F polypeptide at a certain concentration of a test compound or in the absence of said test compound,
• ii) determining the activity of said polypeptide at a different concentration of said test compound.

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising the steps of

• i) determining the activity of a 5-HT1F polypeptide at a certain concentration of a test compound,
• ii) determining the activity of a 5-HT1F polypeptide at the presence of a compound known to be a regulator of a 5-HT1F polypeptide.

A method of screening for therapeutic agents useful in the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising the steps of

• i) contacting a test compound with a 5-HT1F polynucleotide,
• ii) detecting binding of said test compound to said 5-HT1F polynucleotide.

A method of diagnosing a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising the steps of

• i) determining the amount of a 5-HT1F polynucleotide in a sample taken from said mammal,
• ii) determining the amount of 5-HT1F polynucleotide in healthy and/or diseased mammals.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising a therapeutic agent which binds to a 5-HT1F polypeptide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a 5-HT1F polypeptide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising a 5-HT1F polynucleotide.

A pharmaceutical composition for the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising a 5-HT1F polypeptide.

A method for the treatment of a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases in a mammal comprising administering to a mammal an effective amount of a regulator of 5-HT1F.

A method for the regulation of 5-HT1F activity in a mammal having a disease selected from hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases comprising administering to a mammal an effective amount of a regulator of 5-HT1F.